J J Boelens
Overview
Explore the profile of J J Boelens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meesters-Ensing J, Admiraal R, Ebskamp L, Lacna A, Boelens J, Lindemans C, et al.
Front Pharmacol
. 2024 Aug;
15:1444228.
PMID: 39166114
[This corrects the article DOI: 10.3389/fphar.2022.828094.].
2.
Meesters-Ensing J, Admiraal R, Ebskamp L, Lacna A, Boelens J, Lindemans C, et al.
Front Pharmacol
. 2022 Apr;
13:828094.
PMID: 35370695
Anti-thymocyte globulin (ATG), a polyclonal antibody, is used in allogeneic hematopoietic cell transplantation (HCT) to prevent graft-vs.-host-disease (GvHD) and graft failure (GF). Overexposure to ATG leads to poor early T-cell...
3.
Uppugunduri C, Huezo-Diaz Curtis P, Nava T, Rezgui M, Mlakar V, Mlakar S, et al.
Pharmacogenomics J
. 2021 Oct;
22(1):9-18.
PMID: 34711928
Acute Graft versus Host Disease (aGvHD) grades 2-4 occurs in 15-60% of pediatric patients undergoing allogeneic haematopoietic stem-cell transplantation (allo-HSCT). The collateral damage to normal tissue by conditioning regimens administered...
4.
Nataraj R, Hiwarkar P, Bonney D, Campbell H, Jones S, Deambrosis D, et al.
Bone Marrow Transplant
. 2021 Oct;
57(1):38-42.
PMID: 34608276
Umbilical cord blood is the preferred donor cell source for children with Inherited Metabolic disorders undergoing Hematopoietic Cell Transplant (HCT), and its use has been associated with improved "engrafted survival"...
5.
Versluys A, Boelens J, Pronk C, Lankester A, Bordon V, Buechner J, et al.
Bone Marrow Transplant
. 2021 Mar;
56(6):1485.
PMID: 33723414
No abstract available.
6.
Versluys A, Boelens J, Pronk C, Lankester A, Bordon V, Buechner J, et al.
Bone Marrow Transplant
. 2021 Jan;
56(6):1426-1432.
PMID: 33469191
The impact of conditioning regimen prior to hematopoietic cell transplant (HCT) in pediatric AML-patients is not well studied. We retrospectively analyzed the impact of Busulfan-Cyclophosphamide (BuCy), Busulfan-Cyclophosphamide-Melphalan (BuCyMel) and Clofarabine-Fludarabine-Busulfan...
7.
Smits B, Lelieveld P, Ververs F, Turkenburg M, de Koning C, van Dijk M, et al.
Clin Immunol
. 2019 Aug;
212:108248.
PMID: 31382036
No abstract available.
8.
Admiraal R, Boelens J
Handb Exp Pharmacol
. 2019 Aug;
261:471-489.
PMID: 31375921
Hematopoietic cell transplantation (HCT) is a curative treatment option for both malignant and nonmalignant diseases. Success of the procedure mainly depends on disease control and treatment-related complications. Pharmacotherapy plays a...
9.
Langenhorst J, van Kesteren C, van Maarseveen E, Dorlo T, Nierkens S, Lindemans C, et al.
Blood Adv
. 2019 Jul;
3(14):2179-2187.
PMID: 31324638
Fludarabine is the most frequently used agent in conditioning regimens for allogeneic hematopoietic cell transplantation (HCT). Body surface area-based dosing leads to highly variable fludarabine exposure. We studied the relation...
10.
Admiraal R, Chiesa R, Lindemans C, Nierkens S, Bierings M, Versluijs A, et al.
Bone Marrow Transplant
. 2016 May;
51(10):1376-1378.
PMID: 27159172
No abstract available.